Frank I. Lin, M.D.

The vision of the Targeted Radionuclide Therapy Section is to accelerate the development and clinical translation of novel radionuclide therapy as a treatment modality for cancer. Dr. Lin is interested in and investigates a number of different radionuclides in both clinical and pre-clinical settings, but is particularly interested in somatostatin receptor-positive rare tumors. In addition to agent development and research, Dr. Lin is also involved in the promotion and advancement of the field of radionuclide therapy, including educational pursuits such as the training of future medical practitioners of this promising form of therapy.

Dr. Lin completed his undergraduate work in Biological Sciences at Stanford University and has a Masters degree in Medical Informatics from the University of Utah. After receiving his medical degree from the Medical College of Wisconsin, Dr. Lin pursued training in various fields and is currently board-certified in Nuclear Medicine, Internal Medicine, and Medical Oncology. Dr. Lin has worked at the NCI since 2010, and was selected as a Lasker Clinical Research Scholar in 2016 to be the head of the newly created Targeted Radionuclide Therapy Section housed within the Molecular Imaging Branch headed by Dr. Peter Choyke. Dr. Lin’s research focuses on the translational and clinical evaluation of novel targeted radionuclide therapies to treat cancers, with special interest in somatostatin receptor-positive rare tumors such as pheochromocytomas/paragangliomas and gastroenteropancreatic GI neuroendocrine tumors. He is also very interested in methods to optimize radionuclide therapy approaches using strategies such as combination treatments and radiation dosimetry.